Valuation : OLIPASS Corporation

Market Cap 26.53B 19.13M 16.42M 15.41M 14.08M 26.57M 1.83B 26.7M 182M 70.7M 921M 71.85M 70.29M 3.05B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.67M 12.59M 11.82M 10.79M 20.37M 1.4B 20.46M 140M 54.19M 706M 55.07M 53.87M 2.34B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
141,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 21/05/2025
Corporate Officer/Principal 34 27/11/2024
Comptroller/Controller/Auditor 67 30/03/2025
Director TitleAgeSince
Director/Board Member 54 27/11/2024
Director/Board Member 34 27/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-91.74% 9.71M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.00%+2.51%+49.34%+93.23% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-0.49%+1.73%+59.01%+11.60% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
+0.90%+1.77%+37.30%-17.15% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%-1.59%+13.19%+543.56% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average -0.93%-3.54%+53.71%+168.39% 28.83B
Weighted average by Cap. +1.04%+0.72%+56.53%+157.60%

Financials

2021 2022
Net sales 852M 614K 527K 495K 452K 853K 58.59M 857K 5.86M 2.27M 29.56M 2.31M 2.26M 97.91M 2.3B 1.66M 1.42M 1.33M 1.22M 2.3M 158M 2.31M 15.79M 6.12M 79.68M 6.22M 6.08M 264M
Net income -25.13B -18.13M -15.56M -14.6M -13.34M -25.17M -1.73B -25.29M -173M -66.98M -872M -68.06M -66.59M -2.89B -24.17B -17.43M -14.96M -14.04M -12.83M -24.2M -1.66B -24.32M -166M -64.4M -839M -65.45M -64.03M -2.78B
Net Debt -18.29B -13.19M -11.32M -10.63M -9.71M -18.32M -1.26B -18.41M -126M -48.74M -635M -49.53M -48.46M -2.1B -6.2B -4.47M -3.83M -3.6M -3.29M -6.2M -426M -6.23M -42.6M -16.51M -215M -16.78M -16.41M -712M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock